TRAJENTA DUO 2.5/500 10

About

Trajenta Duo 2.5/500 is a combination medication containing Linagliptin (2.5mg) and Metformin (500mg), primarily used in the management of type 2 diabetes mellitus. Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases the levels of incretin hormones, leading to enhanced glucose-dependent insulin secretion and reduced glucagon secretion. Metformin, a biguanide, works by decreasing hepatic glucose production, reducing intestinal absorption of glucose, and improving insulin sensitivity by increasing peripheral glucose uptake and utilization. This dual mechanism of action provides comprehensive glycemic control, helping to lower blood sugar levels effectively. It is typically prescribed as an adjunct to diet and exercise when monotherapy with either agent is insufficient.

The combination aims to improve glycemic parameters, including fasting and postprandial glucose levels, and reduce glycated hemoglobin (HbA1c). Its clinical utility lies in offering a synergistic approach to managing hyperglycemia, particularly in patients who require more intensive glucose lowering than can be achieved with a single antidiabetic agent. The formulation is designed to provide sustained control over blood glucose, contributing to better long-term outcomes for individuals with type 2 diabetes.

Uses

• Management of type 2 diabetes mellitus.
• Adjunct to diet and exercise for glycemic control.
• Used when monotherapy with Metformin or Linagliptin is inadequate.
• Helps improve fasting and postprandial blood glucose levels.

Directions For Use

Take orally, usually twice daily with meals to minimize gastrointestinal side effects. Follow your doctor's prescribed dosage and schedule.

Benefits

• Effectively lowers blood glucose levels.
• Improves HbA1c significantly.
• Combines two complementary mechanisms of action.
• Generally well-tolerated with a low risk of hypoglycemia.
• May contribute to modest weight loss (due to Metformin).
• Convenient fixed-dose combination.

Side Effects

• Nausea
• Diarrhea
• Abdominal pain
• Vomiting
• Headache
• Nasopharyngitis
• Upper respiratory tract infection
• Hypoglycemia (especially with other antidiabetics)
• Lactic acidosis (rare, serious, Metformin-related)
• Vitamin B12 deficiency (long-term Metformin use)
• Pancreatitis (rare)
• Joint pain

Safety Measures

• Alcohol - Avoid excessive alcohol intake as it can increase the risk of lactic acidosis, a rare but serious side effect associated with Metformin.
• Pregnancy - Generally not recommended during pregnancy. Consult your doctor to discuss risks and benefits, as alternative treatments may be safer.
• Breastfeeding - Metformin passes into breast milk; Linagliptin data is limited. Consult your doctor to weigh potential risks to the infant against benefits to the mother.
• Liver - Contraindicated in severe hepatic impairment due to increased risk of lactic acidosis with Metformin. Use with caution in moderate liver conditions.
• Kidney - Dose adjustment or contraindication is necessary based on eGFR due to the risk of Metformin accumulation and lactic acidosis in renal impairment.
• Lung - No specific direct lung contraindication, but severe respiratory failure can increase the risk of lactic acidosis due to impaired oxygenation.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.